5:49 PM
 | 
Dec 26, 2012
 |  BC Extra  |  Company News

Eisai seeking earlier access for Belviq

Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) sent a letter late last week to the U.S. Drug Enforcement Agency requesting that the agency allow Belviq lorcaserin from partner Arena Pharmaceuticals Inc. (NASDAQ:ANRA) to be available immediately once the agency publishes its final classification of the obesity drug. Last Wednesday, the DEA proposed...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >